Form 4: Adverum Biotechnologies COO Acquires 64,394 Stock Options

Peter Soparkar, Chief Operating Officer of Adverum Biotechnologies, acquired 64,394 stock options on August 2, 2024, according to a Form 4 filing with the SEC.

Summary

• Peter Soparkar, the Chief Operating Officer of Adverum Biotechnologies, Inc., filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on August 2, 2024.
• Soparkar acquired 64,394 stock options with an exercise price of $7.15.
• The options vest over three years, starting August 2, 2024, with one-third vesting on the first anniversary and the remainder vesting monthly thereafter, contingent upon continued service.
• The expiration date for the options is August 1, 2034.
• Following the reported transaction, Soparkar directly owns 64,394 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard executive compensation disclosure. The acquisition of stock options can be viewed as a positive sign of confidence, but it's not a major event.

Positives

• The acquisition of stock options by a key executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track executive compensation and potential alignment of interests.

Stakeholder Impact

• The acquisition of stock options by the COO could potentially align his interests more closely with those of the shareholders.

Key Dates